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In this mini-monograph, “biomonitoring” is
the analytical measurement of biomarkers in
specified units of tissues or body products
(blood, urine, etc.). These biomarkers are any
substances, structures, or processes so meas-
ured that indicate an exposure or susceptibil-
ity or that predict the incidence or outcome
of disease (Toniolo et al. 1997).
Public and private demands for biomoni-
toring data are on the increase. In the United
States, government-sponsored programs
include the National Health and Nutrition
Examination Survey (NHANES) conducted
by the Centers for Disease Control and
Prevention (CDC 2001, 2003, 2005), the
CDC National Environmental Public Health
Tracking Program (CDC 2004), the inter-
agency National Children’s Study (NCS
2005), the interagency Agricultural Health
Study (AHS 2005), the Farm Family
Exposure Study (University of Minnesota
2004), and the pilot studies conducted by the
U.S. Environmental Protection Agency (U.S.
EPA) as part of the National Human
Exposure Assessment Survey (NHEXAS)
(U.S. EPA 2004). The National Institute of
Environmental Health Sciences (NIEHS) and
the U.S. EPA currently sponsor research to
identify relevant environmental exposures in
12 Centers for Children’s Environmental
Health and Disease Prevention Research
around the United States (NIEHS 2003).
The National Academy of Sciences/National
Research Council Committee on Human
Biomonitoring for Environmental Toxicants
has reviewed “current practices and recom-
mends ways to improve the interpretation
and uses of human biomonitoring data for
environmental toxicants” (NRC 2004).
Epidemiology studies, which include a bio-
monitoring component, are also under way in
numerous academic institutions.
In Europe, the European Commission
(EC) has developed background materials for
environmental health, named SCALE
(Scientific evidence, focused on Children,
meant to raise Awareness, improve the situa-
tion by use of Legal instruments, and ensure a
continual Evaluation of the progress made)
(EC 2004a). SCALE was followed by the
European Union’s (EU) environmental
health action plan, with “Action 3” focusing
on biomonitoring. A specific support action
program to prepare a European biomonitor-
ing pilot study in 2007 has been initiated
(EC 2004b). The EU has financed several
research programs that focus on development
and validation of biomarkers.
The European Centre for Ecotoxicology
and Toxicology of Chemicals (ECETOC)
published “Guidance for the Interpretation of
Biomonitoring Data” (ECETOC 2005),
which reviews the purpose and uses of bio-
monitoring data, offers guidance on interpre-
tation, and suggests a framework for placing
biomarker data into context. Also, breast milk
monitoring programs provide surveillance
data for characterizing high-risk population
exposures. So important is the collection of
biomonitoring data that several prominent
European Union ofﬁcials in 2004 gave blood
as part of a World Wildlife Fund (WWF) sur-
vey to demonstrate the presence of environ-
mental chemicals in the human body (WWF
2004). Although these cited examples are by
no means a complete inventory of existing or
planned biomonitoring activities, they provide
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Biomonitoring uses analytic methods that permit the accurate measurement of low levels of
environmental chemicals in human tissues. However, depending on the intended use, biomonitor-
ing, like all exposure tools, may not be a stand-alone exposure assessment tool for some of its envi-
ronmental public health uses. Although biomonitoring data demonstrate that many
environmental chemicals are absorbed in human tissues, uncertainty exists regarding if and at
what concentrations many of these chemicals cause adverse health outcomes. Moreover, without
exposure pathway information, it is difﬁcult to relate biomonitoring results to sources and routes
of exposure and develop effective health risk management strategies. In September 2004, the
Health and Environmental Sciences Institute, U.S. Environmental Protection Agency, Centers for
Disease Control and Prevention, Agency for Toxic Substances and Disease Registry, and
International Council of Chemical Associations co-sponsored the International Biomonitoring
Workshop, which explored the processes and information needed for placing biomonitoring data
into perspective for risk assessment purposes, with special emphasis on integrating biomarker
measurements of exposure, internal dose, and potential health outcome. Scientists from interna-
tional governments, academia, and industry recommended criteria for applying biomonitoring
data for various uses. Six case studies, which are part of this mini-monograph, were examined:
inorganic arsenic, methyl eugenol, organophosphorus pesticides, perﬂuorooctanesulfonate, phtha-
lates, and polybrominated diphenyl ethers. Based on the workshop and follow-up discussions, this
overview article summarizes lessons learned, identifies data gaps, outlines research needs, and
offers guidance for designing and conducting biomonitoring studies, as well as interpreting bio-
monitoring data in the context of risk assessment and risk management. Key words: arsenic, bio-
markers, biomonitoring, exposure, methyl eugenol, organophosphorus, PBDE, PFOS, phthalates,
risk assessment. Environ Health Perspect 114:1755–1762 (2006). doi:10.1289/ehp.9056 available
via http://dx.doi.org/ [Online 12 June 2006]the reader with a snapshot of the magnitude of
global interest in biomonitoring.
The ﬂurry of activity associated with bio-
monitoring data collection reflects, in part,
the risk assessment community’s call for more
and better exposure data, especially in the
context of population-based studies. Now,
risk assessors face the difficult challenge of
how best to interpret and apply biomonitor-
ing data. Although the availability of human
biomonitoring data for many chemicals can
greatly reduce the uncertainty associated with
the use of external exposure estimates in risk
assessment, experience and guidance are
needed to integrate the use of biomonitoring
data into the risk assessment process.
Biomonitoring is not a new phenomenon.
For more than a century, occupational physi-
cians and industrial hygienists have moni-
tored worker populations for exposure to a
variety of hazardous substances. Clinical med-
icine offers historical and contemporary
lessons on the value of measuring human
body fluids for indicators of adverse health
risk (Sexton et al. 2004). Ideally, biomonitor-
ing data from environmental, occupational,
and clinical settings are supported by quality
control, analytical standardization, availability
of control groups, and other mechanisms
for limiting uncertainty and variability.
Biomonitoring programs for assessing expo-
sure to environmental chemicals generally
require the measurement of the relevant ana-
lytes at much lower concentrations than
needed in human clinical or animal toxicol-
ogy studies, thus posing considerable chal-
lenges. Therefore, biomonitoring approaches
for assessing exposures to environmental
chemicals must employ state-of-the-art ana-
lytical methods, which often include isotope-
dilution mass spectrometry, to limit the
uncertainty for measuring low-level concen-
trations. Improved analytical capabilities
make possible the accurate and precise meas-
urement of many environmental chemicals at
very low levels in the tissues of the general
population, thus demonstrating human expo-
sure to and absorption of chemicals, and
often their distribution, metabolism, storage,
and elimination.
On 21–22 September 2004 the Interna-
tional Life Sciences Institute’s (ILSI) Health
and Environmental Sciences Institute (HESI)
organized and co-sponsored the International
Biomonitoring Workshop with the U.S. EPA
National Exposure Research Laboratory, the
CDC National Center for Environmental
Health, the Agency for Toxic Substances and
Disease Registry, and the International
Council of Chemical Associations. The work-
shop was held at the laboratory facilities of
the U.S. EPA in Research Triangle Park,
North Carolina.
At the workshop, key questions relating to
the use of biomonitoring data in the context
of risk assessment were discussed: How can
biomonitoring data be used? What other
information is needed to apply biomonitoring
data in a risk assessment context? How might
biomonitoring data be used inappropriately?
To explore these questions, case studies were
prepared in advance and discussed in small
working groups. The case studies included
chemicals that are short-lived in the environ-
ment and readily metabolized in humans, as
well as chemicals that are relatively stable in
the environment and bioaccumulate. Some
case studies were data rich and were com-
pared and contrasted with chemicals for
which few data exist. This mini-monograph
includes six case studies examined at the
workshop. In evaluating the case studies,
workshop participants identiﬁed both general
and specific scientific issues, questions, and
research needs.
The environmental public health contin-
uum (EPHC; Figure 1) served as an impor-
tant starting point for the 100 workshop
invitees from international governments,
academia, and industry. The workshop
focused on the links between the components
of the EPHC as well as on the components
themselves. The unique utility of the EPHC
as a tool is that one may start at any point on
the continuum and work forward or back-
ward through the links. Because the links
work both ways, it is possible to examine
what is not known and which data gaps need
to be filled. Careful definition of the link
being assessed, as well as the question being
asked, is critical.
At the International Biomonitoring
Workshop, participants explored the processes
and information needed to place biomonitor-
ing data into perspective for the risk assess-
ment process, with special emphasis on
integrating biomarker measurements of expo-
sure, internal dose, and potential health out-
come. The EPHC was modiﬁed to capture the
critical workshop focus area (Figure 2). The
reliance on and integration of hazard identiﬁ-
cation with exposure and dose are recognized
in this diagram.
One outcome of the workshop is the
development of guidance on the application
of biomonitoring data in the context of risk
assessment, risk management, and disease pre-
vention. Different criteria are recommended
for applying and interpreting biomonitoring
information for different purposes. For
instance, epidemiology/human effects data
would not be needed to address the question
of whether there is a trend for a substance or
an increase (or decrease) in the environment
over time; however, epidemiology/human
effects data (and or animal toxicology data)
would be necessary if the question being
asked is whether there is a potential human
health risk from exposure to the substance.
The risk assessor/risk manager will use differ-
ent data and criteria depending on the ques-
tion (Doerrer and Holsapple 2004). The
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Figure 1. The environmental public health continuum (EPHC).
Figure 2. Focus area for the September 2004 International Biomonitoring Workshop. 
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• Population(s)guidance, criteria, and questions outlined
here are a general starting point for designing
and conducting biomonitoring studies, as
well as interpreting biomonitoring data
in the context of risk assessment and risk
management.
Analytical Methods/
Biomarkers of Exposure
The case studies reviewed in this mini-
monograph address the ability of the analytical
methods to measure the analytes of interest for
the stated biomonitoring purposes: 
• For phthalates, the ubiquitous occurrence
of this chemical class necessitated a focus
on their metabolites, specifically the
monoesters—the presumed toxicologically
relevant form of the chemical (Calafat and
McKee 2006). For purposes of this mini-
monograph, di(2-ethylhexyl) phthalate
(DEHP) and diethyl phthalate (DEP) were
examined as case studies. It should be noted
that, in the case of DEHP, additional
metabolites, which have higher urinary con-
centrations and thus are more sensitive indi-
cators of exposure to DEHP than the
monoester, can also be measured. 
• For methyl eugenol, the parent compound
can be measured in serum, which is an indi-
cation of exposure. However, the toxicologi-
cally relevant metabolite may be the
DNA-reactive 1´-hydroxy species (Robison
and Barr 2006). 
•For arsenic, it is important to identify
whether organic or inorganic forms are of
primary interest, as well as the valence state
(III or V) (Hughes 2006). 
• Analytical methods for measuring perﬂuoro-
octanesulfonate (PFOS) in serum have been
established and are undergoing further
reﬁnement (Butenhoff et al. 2006). Based on
a growing body of literature, there is evi-
dence that PFOS distributes mainly in blood
and liver, where it is bound to protein, is not
readily metabolized, and has an elimination
half-life of several years in humans. 
• The organophosphorus pesticides are rapidly
metabolized and excreted in the urine (Barr
and Angerer 2006). Many methods have
been used for measuring the common
metabolites of malathion and chlorpyrifos,
the two organophosphorus pesticides exam-
ined in this mini-monograph. In most
instances, the comparability of these meth-
ods has not been established, although ana-
lytical techniques using high-performance
liquid chromatography interfaced with tan-
dem mass spectrometry provide the most
reliable data. In addition, many of the
organophosphorus metabolites measured can
be derived from environmental exposures to
the preformed metabolite itself, complicat-
ing interpretation of the biomonitoring data
(Barr and Angerer 2006). 
•The polybrominated diphenyl ethers
(PBDEs) are ubiquitous in the environ-
ment, and there is evidence that some of
their congeners bioaccumulate. The PBDEs
are normally found as a mixture of con-
geners, but speciﬁc congeners can be meas-
ured when assessing exposure to the
commercial products containing the penta-
and octabromodiphenyl ethers (Birnbaum
and Cohen Hubal 2006).
As noted, the selection of the proper metabo-
lites for the biomonitoring program is impor-
tant. Similarly, the performance of the
laboratory cannot be overstated. Every bio-
monitoring laboratory should participate in
inspections such as those conducted in the
United States according to the Clinical
Laboratory Improvement Amendments
(CLIA 1988) and participate where available
in interlaboratory studies. One such demon-
stration of needs of interlaboratory compari-
son data is given in the inorganic arsenic case
study (Hughes 2006). Reference standards
and human urine samples were spiked with
different amounts of the same species of
arsenic and analyzed by different laboratories.
When the arsenic levels in the urine samples
were at concentrations that are relevant to
research on the metabolism of arsenic in
humans (> 5 µg/L), the variance between
laboratories was low. However, when arsenic
levels were lower (< 5 µg/L), there was consid-
erably more variation, especially in methods
for which the detection limits were in the
range of 1–5 µg/L. Clearly, this indicates poor
interlaboratory comparison at lower concen-
trations that is, in large part, due to differ-
ences in analytical methods.
The strategy used to collect samples for
biomonitoring needs to be carefully devel-
oped. For example, in the inorganic arsenic
case study, sampling strategy was considered,
but historical experience indicates that there is
relatively little intraindividual variability in
urinary arsenic levels (Hughes 2006). Thus,
sampling time may be less of a consideration
for an individual. However, because of poten-
tial problems with arsenic in seafood, which
can confound exposure results based only on
total arsenic urinary analysis, subjects should
refrain from consuming seafood for a few
days before urine collection. Also, there may
be differences in the metabolism and excre-
tion of inorganic arsenic between children
and adults (Concha et al. 1998). Thus, con-
sideration of age of the population studied
may be important for arsenic exposure analy-
sis. By contrast, methyl eugenol is rapidly
absorbed from the gastrointestinal tract and
metabolized to multiple species, including
hydroxy acids, O-demethylation, and hydrox-
ylation of the benzene ring (Robison and Barr
2006). In one human uptake study, sampling
was conducted at fixed time points after
ingestion of cookies containing methyl
eugenol (Schecter et al. 2004). The results of
this study indicate that serum methyl eugenol
concentrations peak approximately 1 hr after
an acute exposure and are close to pre-
exposure or background levels approximately
2 hr after ingestion. Because methyl eugenol
is a naturally occurring chemical found in
spices and herbs, such as allspice and basil,
any biomonitoring study should also include
consideration of dietary habits. In the case of
the human uptake study, fasted subjects were
used, which greatly reduced the potential
variability caused from concurrent exposures
to methyl eugenol through the normal diet.
Nevertheless, existing background levels,
albeit low, suggest that some portion of the
methyl eugenol resides in a third compart-
ment, potentially adipose tissue, which is in
equilibrium with its blood concentration.
The phthalates case study highlights an
additional consideration for sampling strat-
egy, that is, knowledge about potential
sources of sample contamination (Calafat and
McKee 2006). Because DEP and DEHP are
relatively ubiquitous materials that can be
found in plastics (DEHP) and soaps/cleaning
solutions (DEP), laboratory containers and
cleaning solutions that contain fragrances are
potential sources of contamination. As illus-
trated in the case study, a straightforward
solution to this sampling problem was to
measure phthalate metabolites in urine rather
than the parent compounds.
Given the lessons learned from the case
studies, several key questions regarding ana-
lytical approaches for biomonitoring should
be considered:
• Were standard reference materials used that
were prepared in the biologic matrix of
interest (matrix based)?
• What are the specificity and sensitivity of
the analytical method?
• Is the biomarker of exposure valid for the
intended use (i.e., Does it accurately reﬂect
the intended use?) [Validity is deﬁned as the
(relative) lack of systematic measurement
error when comparing the actual observa-
tion with a standard. Validity differs from
reliability in that reliability is the extent to
which an experiment or measurement pro-
cedure yields the same results (tendency
toward consistency) on repeated trials.]
• Have there been intra- or interlaboratory
comparisons of methods?
• Did the sampling strategy include consider-
ation of toxicokinetics?
• Did the sampling strategy include consider-
ation of potential sources of error or sample
contamination?
• Did the sampling strategy include consider-
ation of the stability of the compound in
question with respect to the appropriateness
of sample collection and storage methods? 
Use of biomonitoring data in risk assessment
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Biomonitoring data represent an integration
of exposure from all sources and routes,
which provides an important perspective on
overall exposure. Collection of serial biomoni-
toring samples over an extended period of
time can provide information regarding vari-
ability and trends in exposure. Such informa-
tion is particularly useful for assessing the
effectiveness of environmental remediation
programs or evaluating the impact of removal
or reduction in general use of a chemical (e.g.,
lead). However, the primary sources of expo-
sure for many of the case study chemicals dis-
cussed in this mini-monograph are not fully
understood. For example, in the case of DEP,
it is known that fragranced cosmetic and
other consumer products may contain DEP;
however, the use of DEP in the cosmetic and
fragrance industry accounts for < 20% of all
DEP production (Api 2001). Consequently,
many other sources of exposure are likely to
contribute to the human DEP body burden.
Potential sources of exposure to DEHP are
numerous (e.g., medical plastics such as tub-
ing and syringes; household materials such as
floor or wall coverings, and plastic toys)
(Calafat and McKee 2006).
Organophosphorus pesticides are used
widely in agriculture and to a lesser extent in
residential applications. Because organophos-
phorus pesticide residues have been detected at
permissible (and sometimes impermissible)
levels in many agricultural products, low-level
dietary exposures to organophosphorus pesti-
cides are likely. Other potential sources of
exposure to a few organophosphorus pesticides
still registered for residential uses include pre-
construction termite control and home and
garden use. In general, occupational exposures
to organophosphorus pesticides dwarf envi-
ronmental exposures (Barr et al. 2004, 2005);
however, special populations, such as farm-
worker children, may receive higher exposures.
General population exposures based on bio-
monitoring data appear low whether or not
the contribution from exposures to preformed
metabolites is considered.
PBDEs and PFOS are ubiquitous in the
environment and have been detected in vari-
ous human biologic samples. PBDEs are
found in hard plastics, electronics, textiles,
and polyurethane foam products. Past or cur-
rent commercial uses of PFOS predominantly
include surface treatments for soil- and stain-
resistant coating on fabrics, carpets, and
leather; coatings on paper and packaging
products for grease and oil resistance, includ-
ing food contact papers; and performance
chemical uses, such as ﬁre-extinguishing foam
concentrates, mining and oil surfactants, elec-
troplating and etching bath surfactants,
household additives, chemical intermediates,
coatings and coating additives, carpet spot
cleaners, and insecticide raw materials.
Although the uses of PBDEs and PFOS have
been identified, little is known about the
sources of exposure and how PBDEs and
PFOS enter the environment (Birnbaum and
Cohen Hubal 2006; Butenhoff et al. 2006).
Although both PBDEs and PFOS have been
used in various consumer products, neither of
these classes of chemicals was expected to be
found in measurable levels in human tissues,
given their specific chemical properties and
uses. Environmental and ecologic monitoring
data such as dust levels, market basket sur-
veys, and ﬁsh and wildlife surveys can help to
identify sources of exposure and shed light on
where research should be focused.
In the case of PFOS, significant geo-
graphic differences in human concentrations
indicate that different exposures have
occurred (Butenhoff et al. 2006). North
Americans, particularly those in the south-
eastern United States, are generally more
exposed than are Europeans or Asians. Sex-
related differences have been reported incon-
sistently in U.S. populations. Japanese studies
have reported higher PFOS concentrations in
men. As discussed in Butenhoff et al. (2006),
the mechanisms and pathways leading to the
presence of PFOS in human blood are not
well characterized but likely involve exposure
to environmental PFOS or precursor mole-
cules and residual levels of PFOS or PFOS
precursors in industrial and commercial prod-
ucts. This highlights the need to develop a
better understanding of the potential for these
compounds to persist in the environment, as
well as their environmental fate. Based on the
biomonitoring data available for PFOS and
PBDEs in the United States, the range of bio-
logic values in the general population is quite
large, and the data are log-normally distrib-
uted (Birnbaum and Cohen Hubal 2006;
Butenhoff et al. 2006).
Arsenic is an example of a chemical that
occurs naturally in the environment and is
also introduced as a result of human activity.
This further illustrates the need for a detailed
understanding of potential sources of expo-
sure and how those sources contribute to
overall exposure. In addition, multiple species
of arsenic must be considered potential bio-
markers of exposure. The diet is a major
source of nonoccupational exposure to
arsenic, which can be in inorganic and
organic forms. Certain types of seafood (e.g.,
shrimp) contain arsenobetaine, a relatively
nontoxic organic form of arsenic. Drinking
water contains predominantly inorganic
arsenic and can be a significant source of
arsenic exposure. Furthermore, although diet
is the primary route of general population
arsenic exposure, arsenic is also found in the
soil and air; thus, inhalation and dermal
absorption are additional routes of exposure.
Inhalation can be a significant route of 
occupational exposure to inorganic arsenic
(Hughes 2006).
The biomonitoring data for methyl
eugenol suggest no sex, racial, and ethnic expo-
sure differences (Barr et al. 2000). Lifestyle
differences, such as wine consumption
(De Simon et al. 2003) and occupational set-
ting (agricultural use), can also contribute to
exposure (Vargas et al. 2000). Because methyl
eugenol is found in air, water, and some foods,
spices, and oils (Barr et al. 2000; Smith et al.
2002), day-to-day variation in food consump-
tion can significantly affect blood levels of
methyl eugenol. Furthermore, because methyl
eugenol is rapidly metabolized, sampling and
analysis (matrix) strategies can also affect
biomonitoring of this chemical. Importantly,
the biomonitoring data for methyl eugenol do
provide information on total exposure to this
chemical, which can be compared with dietary
estimates to provide some perspective on the
fraction of exposure from food consumption.
Based on the discussions on exposure for
each case study, the following questions
should be considered when designing, con-
ducting, or interpreting exposure studies in
the context of biomonitoring:
• Have the primary sources of exposure been
identiﬁed?
•Are the pathways/routes of exposure
understood?
• Can human exposure be related to animal
toxicology studies?
•Is there some understanding of the
exposure–dose relationship?
• What is understood about temporality and
duration of exposure? 
Finally, emerging technologies in molecular
biology (e.g., genomics/proteomics, nano-
technology) can provide greater insights into
environment/gene interactions and can be
integrated with traditional biomonitoring data
to enhance interpretation of issues such as indi-
vidual and population differences (Schwartz
et al. 2005). For example, the use of molecular
approaches may better delineate genetic-based
differences in pharmacokinetics that in turn
might explain differences in biomonitoring
data for different subpopulations. Metabo-
lomics will permit the rapid identification
of metabolic differences in populations.
Development of nanosensor technologies will
greatly facilitate real-time exposure biomoni-
toring (Balshaw et al. 2005). As these emerging
technologies are introduced and applied, seri-
ous discussion is warranted and, in fact, under
way regarding the ethics associated with the
conduct of human pharmacokinetic studies as
related to exposure to environmental chemi-
cals. Resolution and guidance on this issue will
signiﬁcantly inﬂuence the likelihood that such
studies can be conducted and that regulatory
agencies would in turn use such data.
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Ideally, sufﬁcient toxicologic data are available
in humans and animals to compare results for
biomonitoring purposes. In reality, data sets
are often limited. For this mini-monograph
the critical toxicologic effect(s) associated with
each of the case study chemicals is reasonably
well defined. Certain limitations do exist,
however. For example, in the case of methyl
eugenol, the mode of action in animals is not
understood, and there are no known human
health effects associated with dietary ingestion
(Robison and Barr 2006; Schecter et al. 2004).
A number of animal toxicity studies with
methyl eugenol exist, including single- and
multiple-dose toxicokinetic studies. The avail-
able data indicate that methyl eugenol under-
goes relatively rapid metabolic conversion and
excretion (National Toxicology Program
2000; Smith et al. 2002). The rodent bioassay
data indicate that methyl eugenol, along with
some structural analogs and when adminis-
tered at high-bolus doses, may cause a shift in
metabolism, resulting in the formation of a
reactive carbonium ion intermediate. This is
associated with liver tumor induction in
rodents. Although the oral route of exposure is
relevant, use of bolus administration in
rodents contrasts with human exposure via
dietary ingestion of spices and foods contain-
ing methyl eugenol. In addition, low-level der-
mal exposure may occur after the use of
products containing methyl eugenol as a com-
ponent of natural oils. More data are needed
to understand comparative metabolism
between animals and humans, the critical
metabolite(s), and the mode of action.
The toxicology of inorganic arsenic is well
characterized for most end points (Hughes
2006). Inorganic arsenic exposure may result
in a number of different toxic effects, including
cancer, neurotoxicity, genotoxicity, and cardio-
vascular toxicity. However, in contrast to most
chemical carcinogens, an animal model does
not exist for assessing the carcinogenic effects
of inorganic arsenic. With this limitation, the
mode of action for inorganic arsenic carcino-
genesis is not completely understood.
The toxicologic profile of DEP has been
fairly well characterized and was recently
reviewed [World Health Organization
(WHO) 2003]. Although there are limited
toxicokinetic data for DEP, it is possible 
to make some inferences about the toxicoki-
netics of DEP based on information available
for other phthalates (Calafat and McKee
2006). The existing data support the conclu-
sion that there are no substantial differences
in metabolism between humans and rodents.
Quantitative safety assessments for DEP use
one of two no observed adverse effect levels
(NOAELs): one from a dietary study (U.S.
EPA 1993), and one from a developmental
and reproductive toxicity study (WHO
2003). Assessments of exposure (David 2000;
Kohn et al. 2000) indicate that the exposures
based on biomonitoring data are substantially
less than either NOAEL.
Toxicology data indicate that DEHP can
induce liver effects in rodents, including
changes in liver weight, histological changes,
peroxisome proliferation, and tumors (Calafat
and McKee 2006). The International Agency
for Research on Cancer concluded that there
is sufﬁcient evidence of carcinogenicity in ani-
mals but insufficient evidence in humans
(IARC 2000). There is also evidence that high
doses of DEHP can cause developmental and
reproductive toxicity. In recent years these
effects of DEHP have received more attention
than the carcinogenic effects. Quantitative
safety assessments for DEHP have used either
an NOAEL for noncancer liver effects or the
more conservative linear extrapolation meth-
ods based on liver tumor induction. Urinary
metabolite data indicate that ambient expo-
sures of the U.S. population to DEHP are
lower than the reference dose (RfD) estab-
lished by the U.S. EPA, although use of med-
ical devices may result in much higher
exposures to DEHP (Calafat and McKee
2006). However, the use of medical devices
entails risk–beneﬁt calculations that make the
risk assessments substantially different from
those relating to ambient exposures.
The toxicity of PBDE mixtures has been
studied in mammals (Birnbaum and Cohen
Hubal 2006). This case study highlights some
of the considerations that are needed when
evaluating the toxicity of mixtures and their
individual components. Recently, concerns
have been expressed regarding the potential of
PBDEs to cause endocrine-related effects (i.e.,
PBDEs are antiandrogenic and perturb estro-
gen and progesterone pathways) or develop-
mental toxicity effects based on their
qualitative structural similarity to polychlori-
nated dibenzo-p-dioxins and polychlorinated
biphenyls (PCBs), although animal toxicity
data suggest that PBDEs are not dioxin-like
but are more similar to PCBs (Chen et al.
2001). The toxicology of the key primary
component molecules, penta-, octa-, and
decabromodiphenyl ethers, has been evalu-
ated. Exposure to pentabromodiphenyl ether
has been associated with hepatic and
endocrine-disruptive effects, developmental
reproductive effects, and, of most concern,
developmental neurotoxicity. Reproductive
effects have been shown in rats, rabbits, and
fish. Octabromodiphenyl ether has been
shown to cause fetal effects at maternally
toxic doses, and contaminating levels of
2,2´,4,4´,5,5´-hexabromodiphenyl ether has
also been reported to induce developmental
neurotoxicity and perturb several hormonal
pathways. Decabromodiphenyl ether (“Deca,”
the commercial mixture) is reported to have
a relatively low order of toxicity, based on
studies conducted to date. There are no long-
term toxicity studies for the PBDE mixtures
or any of the individual PBDEs. Species
differences in PBDE accumulation appear
to exist.
The pharmacokinetic properties of PFOS
are favorable for using serum PFOS con-
centration as a measure of internal dose
(Butenhoff et al. 2006). Good absorption,
lack of known metabolism, distribution pri-
marily in extracellular space, high serum pro-
tein binding (albumin and β-lipoproteins),
and poor elimination in all species studied
combine to establish serum PFOS concentra-
tion as an integration of exposures from vari-
ous sources. In addition, serum PFOS
concentrations can be directly associated with
effects in toxicology studies.
The acute animal and human toxicities of
the organophosphorus pesticides chlorpyrifos
and malathion are well understood. As potent
inhibitors of the enzyme acetylcholinesterase
that breaks down the neurotransmitter acetyl-
choline, symptoms range from nausea, head-
aches, and increased salivation to death,
depending on the magnitude of exposure. The
organophosphorus insecticides are rapidly
metabolized and excreted in urine. Many of
the urinary metabolites of organophosphorus
insecticides are common, preventing the iden-
tiﬁcation of the parent pesticide(s) to which an
individual was exposed. Other urinary metabo-
lites are more selective for a given insecticide.
Measurements of the intact pesticide in blood
are the most speciﬁc indicators of exposure to a
given organophosphorus pesticide; however,
these measurements are complex and may be
hampered by their instability in blood.
Based on the discussions of toxicity for
each case study, the following questions
should be considered when designing, con-
ducting, or interpreting toxicology studies in
the context of biomonitoring:
• Are there sufﬁcient toxicology data, includ-
ing for longer-term exposures?
• Are the routes of exposure in human and
toxicology studies comparable?
•Are toxicokinetic data in animals and
humans available?
• Are the critical effect(s) and mode of action
understood?
• Are the animal data relevant for humans?
• Are matched biologic samples available for
both humans and animals so that the
results can be compared? Or do sufficient
pharmacokinetic data exist to estimate
exposure levels in animal studies? 
Epidemiology
Data from epidemiology studies can provide
the critical information needed to support the
link between human exposure and human
health effects. At the September 2004
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inorganic arsenic case study was used as an
example of epidemiology data that provide
the initial evidence and link to health effects
in humans (Hughes 2006). A number of epi-
demiology studies have shown that both
occupational and environmental exposure to
inorganic arsenic elevates the risk of certain
cancer types, including bladder, skin, and lung.
Similarly, possible health effects related to
organophosphorus pesticide exposures were
studied. Apart from the acute toxic effects that
have been directly attributable to organophos-
phorus pesticide exposures in manufacturers,
applicators, and suicide victims, low-level
environmental exposures to chlorpyrifos
(Berkowitz et al. 2004; Perera et al. 2003;
Whyatt et al. 2004) or organophosphorus
pesticide mixtures (Eskenazi et al. 2004;
Young et al. 2005) and birth outcome or
neurocognitive effects were evaluated in sev-
eral studies. However, the exposure measures
and birth outcomes associated with the expo-
sures differed (Needham 2005).
For the other case study chemicals, there
are limited or no epidemiology data. For
example, for methyl eugenol and PBDEs,
there are no known epidemiology studies;
however, extensive human dietary exposure
data exist (Robison and Barr 2006).
Currently, evidence of human health
effects associated with exposure to DEP or
DEHP is limited (Calafat and McKee 2006).
No epidemiology data for DEHP exist to sug-
gest a carcinogenic effect, and several recent
reviews question whether the existing liver
tumor data in animals are relevant for humans
(IARC 2000; Klaunig et al. 2003). The present
concern for DEHP exposure is the potential
for developmental and reproductive effects. In
several human studies, possible associations
between phthalates, including DEP and
DEHP, and altered semen quality in adults as
well as shortened anogenital distance in baby
boys, and other health end points have been
explored (Calafat and McKee 2006). Because
some of these studies suggest potential adverse
health effects of phthalates, further studies with
larger populations are recommended.
No large-scale epidemiology studies exist
for PBDEs or PFOS (Birnbaum and Cohen
Hubal 2006; Butenhoff et al. 2006). Very lim-
ited human data are available to suggest any
human health effects associated with PBDE
exposure. For PFOS, analyses of occupationally
exposed workers are available, including one
cohort mortality study (Alexander et al. 2003)
that was followed up by a worker health survey
(Alexander 2004). There is some indication
that a higher risk of bladder cancer mortality
exists in some of the highly exposed workers,
but the limited size of the study population pre-
cluded a conclusive exposure–response analysis
(Butenhoff et al. 2006).
The case studies illustrate that, in many
instances, there is an absence of large-scale
epidemiology studies with sufﬁcient statistical
power to detect associations between human
exposure and health effects identiﬁed in ani-
mal toxicology studies. In addition, interpre-
tation of epidemiologic studies is complicated
by the limited ability to accurately determine
dosimetry, exposure duration, and patterns of
exposure. Deﬁning the potential confounding
factors for each chemical is important because
epidemiology studies are often designed to
evaluate a speciﬁc association between chemi-
cal exposure and a known health effect(s).
Several factors should be considered when
designing, conducting, or interpreting epi-
demiologic studies that seek to deﬁne associa-
tions between speciﬁc exposures and speciﬁc
human health effects (or their absence), par-
ticularly in the context of biomonitoring. As
stated previously, careful deﬁnition of the link
being assessed, as well as the question being
asked, is critical.
• Are criteria for making reasonable inferences
of association and causation supported? The
Bradford Hill criteria (Federal Focus 1996),
used successfully in the context of establish-
ing causality in many epidemiology studies,
may have similar utility in biomonitoring
studies. These criteria consist of the follow-
ing basic characteristics: the strength, speci-
ﬁcity, and consistency of the association; the
temporality and duration of exposure; the
biologic gradient or the relationship
between the dose and the response; the
effects of the removal of the suggested cause;
the biologic plausibility of the association;
and the coherence between the association
and other ﬁndings.
• Has an adverse health effect been demon-
strated in humans?
• Is there information regarding the mode of
action for the agent producing this health
effect?
• Are there health effects observed in popula-
tions exposed to the agent of concern?
(Note that some characterization of the
health effects observed in populations
exposed to the agent of concern is needed to
design a new epidemiologic study that is
focused on disease end points. Furthermore,
these health effects must be known before
biomarkers are used to identify population
exposures and assess risk.)
• Are any toxicokinetic and/or toxicodynamic
genetic polymorphisms known to modify
risk and deﬁne susceptible populations?
Risk Assessment/
Risk Management
As noted previously, biomonitoring data can
be used in multiple ways (e.g., trend analysis,
exposure assessment, dose reconstruction),
and supporting data, such as those necessary
for risk assessment purposes, are not always
needed. When biomonitoring data are used
for these non-risk assessment purposes, the
uncertainty associated with their intended
use(s) should be acknowledged and commu-
nicated. In terms of risk assessment and risk
management (e.g., refining remediation
efforts), biomonitoring data have the poten-
tial to be a valuable tool.
Given the increased sensitivity of analyti-
cal methods, simple detection of a chemical in
biologic samples such as blood, urine, breast
milk, or body fat should not be confused with
or equated to increased risk. Exposure infor-
mation must be carefully evaluated against all
relevant toxicology data and any human epi-
demiology data. In addition, the relevance of
the toxicology data to humans should be con-
sidered. There are, based on epidemiology
data, biologically plausible statistical associa-
tions that, taken together with animal and
other toxicologic data, imply causation
between exposure and health effects for inor-
ganic arsenic and organophosphorus pesti-
cides. Evidence suggesting human health
effects associated with exposure to DEP,
DEHP, methyl eugenol, and PFOS is limited
and/or restricted to statistical associations.
For the phthalates, methyl eugenol, and
PBDEs, comparison of exposures based on
the NHANES biomonitoring data that rep-
resent aggregate exposures to all sources
offers suggestive evidence that human expo-
sure in the general population is lower than
NOAELs or RfDs derived from animal toxi-
cology studies (CDC 2001, 2003, 2005).
However, trends in internal concentrations
of certain compounds detected via biomoni-
toring (e.g., rapidly rising PBDE levels in the
United States), as well as the impact on vul-
nerable populations (i.e., highly exposed or
highly susceptible to effects), should also be
considered in assessing risk and making risk
management decisions. Emerging data on
human blood levels of PBDEs for highly
exposed individuals show that there is no
margin of exposure based on several pub-
lished animal studies of developmental or
neurologic toxicity (Birnbaum and Cohen
Hubal 2006).
Based on the discussions of risk assess-
ment and risk management for each case
study, the following questions should be con-
sidered when designing, conducting, or inter-
preting studies for biomonitoring purposes:
• Are there sufﬁcient and relevant toxicology
data?
• Is there a relationship between the bio-
marker of exposure and a known human
health effect?
• Are there pharmacokinetic data that can be
useful in the risk assessment?
• If applicable, is there evidence that remedia-
tion efforts are working?
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Meaningful interpretation of existing and
future biomonitoring data will require rigor-
ous, scientific approaches to data collection,
analysis, interpretation, and application. Thus,
biomonitoring data can provide much-needed
information on exposure to a variety of envi-
ronmental chemicals. However, investigators
must deﬁne and communicate the question to
be addressed in any given biomonitoring
study. For example, the data required for the
assessment and interpretation of exposure
trends may be different from those necessary
for the assessment of health risk. Nonetheless,
the lack of seemingly critical pieces of data for
proper interpretation of biomonitoring data
does not render the biomonitoring data unus-
able. Rather, the existing data gaps add to the
uncertainty of the interpretation of the bio-
monitoring data. Filling these critical data
gaps is essential to reduce these uncertainties
in interpretation, thus providing the most
reliable data for public health decisions.
The authors of this mini-monograph call
for research activities in the following areas
to advance scientiﬁc understanding and appli-
cation of biomonitoring data in its various
contexts:
• Improve the understanding of the predictive
relationships/linkages between measures of
exposure, dose, and effect. Such insight
would allow the development of an inter-
pretation strategy and specific criteria for
moving from any point on the EPHC
(Figure 1) toward either the “exposure” or
“effects” sides.
• Emphasize biomarker validation and preci-
sion. For analytical measurements, conduct
interlaboratory comparison trials.
• Characterize a baseline for biomarkers, and
apply statistical methods to assess temporal
departures from the baseline.
• Improve understanding of the origin of the
biomarker and its relationship to the disease
process and/or individual, multiple, and
exogenous or endogenous exposure. Establish
a database of biomarker disease associations,
including null and negative studies.
• Improve study design to better assess intra-
and interindividual variability related to
measures of exposure, dose, metabolism,
and effects that would influence the likeli-
hood of observing predictive relationships
between these variables and aid in identify-
ing subpopulations that might be at greater
risk. Such data would also clarify the rele-
vance of biomarkers for the target tissues of
certain organs.
•Apply new technologies such as gene
expression, proteomics, and protein activity
profiling, both in terms of development
of potential new biomarkers and as screen-
ing tools for identifying candidates for
biomonitoring.
The questions and considerations identified
in this article for designing, conducting, or
interpreting studies for biomonitoring pur-
poses are intended as guidance only. The
authors acknowledge that no individual study
can address every question. It is recom-
mended, however, that future studies be
designed with some or all of these considera-
tions in mind to maximize application and
interpretation of biomonitoring data for
human health risk assessment.
Government, academic, and industry sci-
entists who are committed to identifying data
needs and exploring research programs
through the HESI consensus-building process
will report progress and technical advance-
ments in biomonitoring in future publications.
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